Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

684TiP - A phase I, open-label, multicenter, dose escalation and expansion study of HM97662 (EZH1/2 dual inhibitor) as a single agent in patients with advanced or metastatic solid tumors

Date

14 Sep 2024

Session

Poster session 01

Topics

Clinical Research;  Tumour Immunology;  Targeted Therapy

Tumour Site

Presenters

Bhumsuk Keam

Citation

Annals of Oncology (2024) 35 (suppl_2): S482-S535. 10.1016/annonc/annonc1589

Authors

B. Keam1, J. Ahn2, K. Kim3, S. Hong4, V. Ganju5, L.E. Lim6, V. Kwatra7, A. Body8, P.D. Rhee9, S. Jung9, J. Yoon9, E. Baek9, Y.S. Noh9

Author affiliations

  • 1 Department Of Internal Medicine, Seoul National University Hospital, 110-744 - Seoul/KR
  • 2 Department Of Oncology, Asan Medical Center - University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 3 Department Of Obstetrics And Gynecology, Seoul National University Bundang Hospital, 13620 - Seongnam/KR
  • 4 Department Of Urology, The Catholic University of Korea - Seoul St.Mary Hospital, 06591 - Seoul/KR
  • 5 Department Of Oncology, Peninsula And Southeast Oncology, 3199 - Frankston/AU
  • 6 Department Of Medical Oncology, Ballarat Regional Integrated Cancer Centre, 3350 - Ballarat/AU
  • 7 Department Of Medical Oncology, Cancer Research South Australia, 5000 - Adelaide/AU
  • 8 Department Of Oncology, Monash Health - Monash Medical Centre, 3168 - Clayton/AU
  • 9 Department Of Onco Clinical Research And Development, Hanmi Pharmaceutical Co., Ltd, 05545 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 684TiP

Background

Enhancer of zeste homolog 2 (EZH2) and its close homolog EZH1 are the enzymatic core subunits of polycomb repressive complex 2 (PRC2). EZH1/2 repress the transcription of target genes by triggering tri-methylation of the lysine 27 residue of histone H3 (H3K27me3). H3K27me3 plays a critical role in cancer progression and is associated with poor prognosis. EZH2 gain-of-function (GOF) mutations or overexpression lead to hyper tri-methylation of H3K27 when loss-of-function mutation of major components of regulatory protein complexes promote cancer pathogenesis by losing its ability to oppose PRC2. Given that EZH1 compensates the activity of EZH2 in EZH2-depleted cells, dual inhibition of EZH1/2 is expected to have a greater anti-tumor activity through suppressing PRC2 function. In preclinical studies, HM97662, a novel EZH1/2 dual inhibitor have demonstrated simultaneous inhibition of the methyltransferase activity of wild-type EZH1/2 as well as GOF mutant EZH2. Given the promising preclinical results, first-in-human phase I study of HM97662 was designed.

Trial design

This is a phase I, open-label, multicenter study of HM97662 as a single agent in patients with advanced or metastatic solid tumors who have failed or are intolerant to standard therapy. Dose escalation part is planned with a 3+3 design to establish the maximum tolerated dose or recommended dose for the randomized dose ranging part. The starting dose is 50 mg once daily (QD) and may proceed to subsequent cohorts increased by 50 mg from the preceding cohort until the maximum dose of 350 mg QD. Randomized dose ranging part is mainly designed with the purpose of dose optimization by evaluating the safety and preliminary efficacy of HM97662 in patients with genomic alterations for more than one feasible doses selected from the dose escalation part. Dose expansion part is designed to assess and confirm the efficacy, safety, pharmacokinetics, and pharmacodynamics of HM97662 with specific target disease determined by available preclinical study results and clinical outcomes. The final analysis will be performed once or separately for each part based on study progression.

Clinical trial identification

NCT05598151.

Editorial acknowledgement

Legal entity responsible for the study

Hanmi Pharmaceutical Co. Ltd.

Funding

Hanmi Pharmaceutical Co. Ltd.

Disclosure

B. Keam: Financial Interests, Personal, Invited Speaker: Merck, Lilly, MSD, LG Chem; Financial Interests, Personal, Advisory Board: Handok, TrialInformatics, ImmunOncia, NeoImmunetech, Beigen; Financial Interests, Personal, Coordinating PI: MSD Oncology, AstraZeneca, Ono Pharmaceutical, Bayer. V. Ganju: Financial Interests, Personal, Other, Honoraria: Roche/Genentech, AstraZeneca. V. Kwatra: Financial Interests, Personal, Advisory Board: Roche. A. Body: Financial Interests, Institutional, Local PI: BeiGene, DayOne, Innovent, Gilead, Hanmi Pharmaceutical, Stingray Therapeutics, Vivace Therapeutics; Financial Interests, Institutional, Research Grant: Cancer Australia (Australian Government). P.D. Rhee, S. Jung, J. Yoon, E. Baek, Y.S. Noh: Financial Interests, Personal, Full or part-time Employment: Hanmi Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.